Clinical trials
-
Colorectal and Solid Tumours – PARP1 Inhibitor M9466 with Topoisomerase 1 Inhibitor-based regimens
Read more: Colorectal and Solid Tumours – PARP1 Inhibitor M9466 with Topoisomerase 1 Inhibitor-based regimensA Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the PARP1 Inhibitor M9466 in Combination with Topoisomerase 1 Inhibitor-based Regimens in advanced solid tumours and colorectal cancer.
-
Lung Cancer – EGFR mutation BG-60366 – 2nd line or more
Read more: Lung Cancer – EGFR mutation BG-60366 – 2nd line or moreA Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics, and Antitumor Activity of a Chimeric Degradation Activating Compound (CDAC) Degrading Epidermal Growth Factor Receptor (EGFR), BG-60366, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
-
Lung Cancer 1st line KRAS G12C PDL1 neg
Read more: Lung Cancer 1st line KRAS G12C PDL1 negA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
-
Ovarian – Platinum Resistant: ZN-C3
Read more: Ovarian – Platinum Resistant: ZN-C3This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3 in combination with other drugs.
-
Lung Cancer PD-L1 <50% 1st line met
Read more: Lung Cancer PD-L1 <50% 1st line metThis study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
-
Breast ER+/HER2- 2nd line met: OP-1250-301 (OPERA-01)
Read more: Breast ER+/HER2- 2nd line met: OP-1250-301 (OPERA-01)This phase 3 clinical study compares the safety and efficacy of OP-1250 to the standard of care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on at least one endocrine therapy in combination with a CDK4/6 inhibitor.